German cancer specialist Catalym GmbH has raised US$150m to finance proof-of-concept studies.
Tag Archive for: CatalYm GmbH
Munich-based immunooncology specialist CatalYm GmbH wants to use €50m from a Series C financing round to advance its anti-GDF15 antibody to Phase II development.